Ciapponi A, Barreira F, Perelli L, et al. - Given the necessity for an optimal trypanocidal therapy, among other control interventions, for Chagas disease that results in achievement of the best possible compliance to cure active infection, particularly in children and young populations, women prior to becoming pregnant to limit congenital transmission, and chronic populations who are currently not being treated and with a risk of progression to cardiomyopathy. Few studies have reported equivalent efficacy of a simple fixed-dose scheme of benznidazole vs the dose adjusted by weight for the treatment of adults seropositive to T. cruzi without clinically evident chronic Chagas cardiomyopathy. Researchers sought to appraise this potential equivalence of schemes via conducting a rigorous systematic review and meta-analysis of randomized controlled trials by reviewing and analyzing the totality of available literature on the topic. From 655 identified records, 10 studies (four of them ongoing) met the inclusion criteria. Despite no direct evidence was gained addressing this question, it seems that an adjusted dose is probably equivalent with respect to important safety and efficacy outcomes, while there remains uncertainty concerning the effect on critical outcomes. As there is no ongoing study comparing fixed vs adjusted doses of benznidazole, an individual patient data network meta-analysis has been undertaken to address this question.